Close menu

June 25th, 2021 | 12:36 CEST

Nordex, XPhyto Therapeutics, Siemens AG - Growth without end

  • Biotechnology
Photo credits:

The Federal Reserve paves the way. After discussions around possible early interest rate hikes flared up last week on the occasion of the Federal Reserve's Open Market Committee, FED head Jerome Powell came forward in person yesterday and dampened burgeoning inflation concerns. While the effects of the pickup in economic activity at the end of the Corona pandemic were stronger than forecast, they should fade over time. Therefore, the loose monetary policy will continue to drive growth - a breeding ground for development and technology stocks and further rising prices.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: NORDEX SE O.N. | DE000A0D6554 , XPHYTO THERAPEUTICS | CA98421R1055 , SIEMENS AG NA O.N. | DE0007236101

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    XPhyto Therapeutics - On many feet

    After the past difficult months due to the Corona pandemic, the 3 words - tested, vaccinated, recovered - have brought some peace. Nevertheless, the virus remains and will return in ever-changing forms. The global diagnostics market is booming and is expected to continue to grow in the coming years. Studies show that the global rapid test market will grow at a compound annual growth rate of 8.9% per year to reach a volume of USD 39.1 billion by 2023. Alongside major players such as Abbott Laboratories and F. Hoffmann-La Roche AG, XPhyto Therapeutics, founded in 2017, is looking to take off. The life sciences accelerator, which has grown through several acquisitions and collaborations, focuses on investing in next-generation drug delivery, diagnostics and new pharmaceutical compounds.

    XPhyto announced in late May that its German partner, Max Pharma GmbH, has begun selling its 25-minute Covid-19 RT-PCR testing system, "Covid-ID Lab" in Germany. Covid-ID Lab is registered within the European Union as a commercial in vitro diagnostic test (CE-IVD). The advantage of the test offered is that Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of sample preparation.

    According to management, the product is intended to bridge the gap between single-use antigen tests and centralized, automated PCR systems. Target customers include airports, cruise ships, pharmacies, medical care facilities, and industrial and educational sites where rapid, meaningful results are needed. The venture was funded by the German Federal Ministry of Education and Research, among others.

    XPhyto Therapeutics can also report important successes in the field of drug development. In the mescaline synthesis program launched at the beginning of the year, the Canadian Company has set itself to use psychedelic substances to develop new drugs to improve the treatment of mental illnesses such as depression, anxiety, addiction and trauma-related stress disorders - without side effects.

    The production of pharmaceutical-grade and industrial-scale psychedelic compounds, including mescaline and psilocybin, is an integral part of XPhyto's psychedelic medicine program and will provide a basis for drug formulation and clinical validation work. This division also relies on collaborations. The Company has an exclusive development agreement with a German university for the industrial biotechnological production of pharmaceutical-grade psilocybin. A similar agreement exists with the University of Alberta for the active ingredient mescaline.
    XPhyto Therapeutics has several irons in the fire because of the Company's revolutionary PCR technology and innovative drug delivery formulations, which are also expected to be launched this year. The stock market value is currently around CAD 135 million and offers a promising entry opportunity at the current level.

    Nordex AG - Orders on a flowing conveyor belt

    A successful week in terms of the order books for wind turbine manufacturer Nordex. A significant order from Finland was already announced at the beginning of the week. Thus, the Hamburg-based Company will be supplying a total of 35 turbines with a total capacity of 199.5 megawatts for the construction of four onshore wind farms in the far north in 2022.

    Yesterday, this was followed by a major order from South America. AES Brasil commissioned Nordex to supply and install 55 N163/5.X turbines for the 313.5 MW Cajuina wind farm. The scope also includes a five-year service contract, which can be extended to up to 20 years through several extension options. Construction of the turbines is scheduled to start in the summer of next year.

    As already reported, following the sharp sell-off, Nordex AG stock is currently bottoming out in the area between the low for the year of EUR 16.59 and EUR 17.10. A sustained rise above this resistance is expected, and a sustained overcoming of the resistance at EUR 19.78 would complete the consolidation formation on the upside. Should the share of the wind turbine manufacturer fall below the low for the year, the striking support zone at EUR 13.87 would be the next target.

    Siemens AG - Like clockwork

    Do you still remember 20.3.2020? Many Siemens shareholders must have been sitting in front of the computer at that time, far less relaxed as the share price marked a new low at EUR 53.19. Today, 1 year and 3 months later, the German flagship Company shines at EUR 135. The restructuring of the Group and the spin-off of the energy sector have been successfully implemented in recent years. Now the Munich-based Company around the new CEO Roland Busch wants to accelerate growth once again. In the run-up to Capital Markets Day, it was announced that comparable sales are expected to grow by an average of 5 to 7% per year over the next three to five years.

    As a result of the "favorable business development" continuing in the current quarter, Siemens is thus also reaffirming its forecast for the full year. However, this outlook includes the burdens of the acquisition of US cancer specialist Varian by medical technology subsidiary Siemens Healthineers. The targets for profit after tax are thus between EUR 5.5 billion and EUR 6.2 billion. It was also announced that the Group is planning to increase dividends gradually and is aiming for a share buyback program of up to EUR 3 billion.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by André Will-Laudien on June 21st, 2024 | 07:00 CEST

    Biotech: What counts is selection! Bayer, Vidac Pharma, Formycon, and Evotec in focus

    • Biotechnology
    • Pharma
    • Biotech

    The biotech sector has so far been unable to keep pace with the high-tech-heavy NASDAQ. However, there are now signals from the central banks that a turnaround in interest rates is imminent. This is because, on the one hand, the US economy is weakening, and on the other hand, inflationary pressure appears to be easing. With lower interest rates, life science companies can refinance themselves more cheaply. Due to the different dynamics, it is now important to fish out the pearls. We select attractive entry levels.


    Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST

    BioNTech, dynaCERT, Plug Power - A single piece of news can change everything

    • Hydrogen
    • greenhydrogen
    • Biotechnology

    Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.


    Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST

    Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors

    • Biotechnology
    • Pharma

    In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?